-
公开(公告)号：US20170159052A1
公开(公告)日：2017-06-08
申请号：US15324572
申请日：2015-07-09
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT
Inventor： Hendrikus Antonius Rudolfus VAN WYK
IPC: C12N15/113
CPC classification number: C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2320/33
Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher syndrome type 2A and/or USH2A-associated non syndromic retina degeneration.
-
公开(公告)号：US20170014237A1
公开(公告)日：2017-01-19
申请号：US15124412
申请日：2015-03-10
Applicant: Stichting Katholieke Universiteit, more particularly Radbound Universiteit Nijmegen , DSM IP Assets B.V.
Inventor： Jacob KOENEN , Edwin DAAMEN , Tony van TIENEN , Pieter BUMA
CPC classification number: A61F2/3872 , A61B34/10 , A61B2034/108 , A61F2/30756 , A61F2/30965 , A61F2002/30014 , A61F2002/30016 , A61F2002/30065 , A61F2002/30067 , A61F2002/30069 , A61F2002/3007 , A61F2002/3008 , A61F2002/30131 , A61F2002/30133 , A61F2002/30578 , A61F2002/30754 , A61F2002/30757
Abstract: The invention is directed to a meniscus prosthesis comprising an arc-shaped meniscus prosthesis body having a main portion (1) comprising a reinforcing part (2) and two end portions (1A, 1B) comprising fixation parts (2A, 2B), wherein the main portion (1) comprises a part made of a first biocompatible, non-resorbable material extending between the two end portions (1A, 1B), wherein the reinforcing part (2) and the fixation parts (2A, 2B) are made of a second biocompatible, non-resorbable material and wherein the reinforcing part (2) extends between the fixation parts (2A, 2B) and wherein the fixation parts (2A, 2B) have a through hole (3A, 3B), the first biocompatible, non-resorbable material has a tensile modulus of at most 100 MPa as determined by ISO 527-1 and the second biocompatible, non-resorbable material has a tensile modulus of at least 101 MPa as determined by ISO 527-1.
Abstract translation: 本发明涉及一种弯液面假体，其包括具有包括加强部分（2）的主要部分（1）和包括固定部分（2A，2B）的两个端部部分（1A，1B）的弧形半月板假体，其中， 主要部分（1）包括在两个端部（1A，1B）之间延伸的第一生物相容不可吸收材料制成的部分，其中加强部分（2）和固定部分（2A，2B）由 第二生物相容性不可吸收材料，并且其中所述加强部分（2）在所述固定部分（2A，2B）之间延伸，并且其中所述固定部分（2A，2B）具有通孔（3A，3B），所述第一生物相容的， - 可吸收材料具有根据ISO 527-1确定的至多100MPa的拉伸模量，并且第二生物相容性不可再吸收材料的拉伸模量通过ISO 527-1确定为至少01MPa。
-
公开(公告)号：US20170003306A1
公开(公告)日：2017-01-05
申请号：US15106727
申请日：2014-12-18
Inventor： Giacinto SCOLES , Fabio DEL BEN , Matteo TURETTA , Wilhelm HUCK , Aigars PIRUSKA
IPC: G01N33/84
CPC classification number: G01N33/84 , G01N2800/7028
Abstract: The present invention relates to a method for detecting circulating tumour cells (CTCs) in body fluids, preferably in blood and lymph.In particular, the method for detecting circulating tumour cells in a body fluid comprises a step of detecting a change in pH and/or in a concentration of at least one molecule selected from lactic acid, lactate ions and protons within an isolated volume of said body fluid in which a cell has been encapsulated.
Abstract translation: 特别地，用于检测体液中的循环肿瘤细胞的方法包括检测所述体内分离体积内的选自乳酸，乳酸离子和质子中的至少一种分子的pH和/或浓度变化的步骤 细胞已被包封的流体。
-
公开(公告)号：US20160326152A1
公开(公告)日：2016-11-10
申请号：US15216884
申请日：2016-07-22
Applicant: Compound Handling B.V. , Stichting Katholieke Universiteit
Inventor： Onno Van Hooij , Jacobus Antonius Schalken , Hendrik Engelbertus Vietor , Dennis Patrick Piet , Petrus Emmanuel Marie Maas , Johann Heinrich Tijhuis , Sirik Deerenberg , Nanda Elisabeth Sprenkels , Siu Ha Tang
IPC: C07D417/04 , A61K31/428 , A61K31/454 , A61K31/4184 , C07D417/14 , A61K45/06 , C07D403/04
CPC classification number: C07D403/04 , A61K31/4155 , A61K31/4184 , A61K31/428 , A61K31/454 , A61K45/06 , C07D417/04 , C07D417/14
Abstract: A compound having the structure according to formula III wherein: X is NH or S; R1 is H or (1C-4C)alkyl; R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy, phenylthio, halogen, or nitro; R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, a monocyclic non-aromatic ring having one or more N-, O- or S-atoms in the ring, each optionally substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, halogen, nitro or (1C-2C)dioxol forming a ring; or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1C-6C)alkyl, phenyl(1C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H, Cl, F, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; R6 is H, (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, nitro or halogen; R7 is H, F, Cl, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; or pharmaceutically acceptable addition salts thereof for use in treatments of carcinoma, in particular, to delay, prevent or reverse metastasis in prostate cancer.
-
公开(公告)号：US20160322089A1
公开(公告)日：2016-11-03
申请号：US15154598
申请日：2016-05-13
Applicant: Stichting Katholieke Universiteit Nijmegen
IPC: G11C11/02
Abstract: A magneto-optical device comprising a magnetic unit and an optical unit, an electronic device comprising the magneto-optical device, a method of energy saving using the magneto-optical device, an array comprising the magneto-optical devices, and a method of changing magnetic orientation.
Abstract translation: 一种包括磁单元和光学单元的磁光装置，包括磁光装置的电子装置，使用磁光装置的节能方法，包括磁光装置的阵列，以及改变 磁性取向。
-
Patent Agency Ranking
公开(公告)号：US20150307948A1
公开(公告)日：2015-10-29
申请号：US14745955
申请日：2015-06-22
Inventor： Daphne Hessels , Gerald Verhaegh , Jack A. Schalken , J. Alfred Witjes
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
Abstract translation: 本文描述了前列腺癌预后的方法，组合物和试剂盒。 该方法包括确定尿样中PCA3和前列腺特异性标志物表达的比例，并将PCA3 /前列腺特异性标志物比值与受试者中前列腺癌的侵袭性和死亡风险相关联。 在患者样品中预测前列腺癌的方法包括评估前列腺癌特异性PCA3 mRNA的量和样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
公开(公告)号：US20150250905A1
公开(公告)日：2015-09-10
申请号：US14428350
申请日：2013-09-14
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT
Inventor： Carl Gustav Figdor , Ingrid Jolanda Monique De Vries , Mangala Srinivas , Luis Javier Cruz Ricondo
IPC: A61K49/22
CPC classification number: A61K49/225 , A61K49/0002 , A61K49/0034 , A61K49/0093 , A61K49/1818 , A61K49/221
Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultra-sound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.
Abstract translation: 本发明涉及造影剂增强医学超声成像。 特别地，提供的造影剂可用于细胞成像和细胞治疗，以及体内靶向，药物递送和灌注或血管成像应用。 更具体地，它提供了包含氟化有机化合物和金属的颗粒。 这样的颗粒可以有利地用于定性或定量成像，例如包括光声和超声成像的声学成像，MRI成像，例如19F成像，包括T1和T2加权成像的1H成像，SPECT，PET，闪烁扫描，荧光成像和光学 相干成像和断层摄影应用。 然后可以将其用于体内和体外的细胞标记，显微镜，组织学或成像脉管系统或灌注成像。
-
公开(公告)号：US20150073019A1
公开(公告)日：2015-03-12
申请号：US14383083
申请日：2013-03-05
Applicant: Compound Handling B.V. , Stichting Katholieke Universiteit
Inventor： Onno Van Hooij , Jacobus Antonius Schalken , Hendrik Engelbertus Viëtor , Dennis Patrick Piet , Petrus Emmanuel Marie Maas , Johann Heinrich Tijhuis , Sirik Deerenberg , Nanda Elisabeth Sprenkels , Siu Ha Tang
IPC: C07D417/14 , C07D417/04 , A61K31/454 , A61K31/428
CPC classification number: C07D403/04 , A61K31/4155 , A61K31/4184 , A61K31/428 , A61K31/454 , A61K45/06 , C07D417/04 , C07D417/14
Abstract: A compound having the structure according to formula III wherein: X is NH or S; R1 is H or (1C-4C)alkyl; R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy, phenylthio, halogen, or nitro; R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, a monocyclic non-aromatic ring having one or more N-, O- or S-atoms in the ring, each optionally substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, halogen, nitro or (1C-2C)dioxol forming a ring; or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1C-6C)alkyl, phenyl(1C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H, Cl, F, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; R6 is H, (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, nitro or halogen; R7 is H, F, Cl, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; or pharmaceutically acceptable addition salts thereof for use in treatments of carcinoma, in particular to delay, prevent or reverse metastasis in prostate cancer.
-
公开(公告)号：US20140017774A1
公开(公告)日：2014-01-16
申请号：US14033699
申请日：2013-09-23
Applicant: The Johns Hopkins University , Stichting Katholieke Universiteit, more particularly The Univ. Medical Centre Nijmegen
Inventor： Marion J.G. Bussemakers , William B. Isaacs
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , A01K2217/05 , A61K38/00 , C07K14/47 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158
Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
Abstract translation: 本发明一般涉及前列腺特异性抗原PCA3。 特别地，本发明涉及编码PCA3蛋白的核酸分子; 纯化的PCA3蛋白和多肽; 重组核酸分子; 含有重组核酸分子的细胞; 具有与PCA3蛋白和多肽特异性结合亲和力的抗体; 含有抗体的杂交瘤; 用于检测编码PCA3蛋白质的核酸的核酸探针; 检测样品中编码PCA3蛋白或多肽的核酸的方法; 含有核酸探针或抗体的试剂盒; 使用本发明的核酸序列，蛋白质或抗体的生物测定来诊断，评估或预测患有前列腺癌的哺乳动物; 治疗用途; 以及预防动物中前列腺癌的方法。
-
公开(公告)号：US20130261171A1
公开(公告)日：2013-10-03
申请号：US13914303
申请日：2013-06-10
Inventor： Daphne Hessels , Gerald Verhaegh , Jack A. Schalken , Alfred J. Witjes
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
-
-
-
-
-
-
-
-
-
Search Results
452
records
(took 0.043 seconds)
